Genotyping of cutaneous melanoma

摘要: Until recently, treatment options for patients with metastatic melanoma were very limited. This landscape has evolved dramatically since the discovery of activating mutations in BRAF gene ~45% cutaneous melanomas. Vemurafenib, dabrafenib, and trametinib have all received regulatory approval a V600 mutation. Based on necessity to document presence mutation prescribe these agents, molecular testing is now standard care this disease. However, rationale are evolving rapidly due an improved understanding drivers heterogeneity melanoma. Such may identify rational combinatorial approaches prevent or overcome resistance approved inhibitors. In addition, new clinical strategies been identified number other changes that detected disease, including somatic NRAS , PTEN CDKN2A c-KIT among others. review summarizes current genetic melanoma, their associations clinicopathological features, implications treatment.